BioVie NE3107 Phase 2 trial: 82% of mild AD patients improved ADAS-Cog12 by 2.6 pts (p=0.0046); Phase 3 50% enrolled

BIOVIE INC.

23-patient open-label Phase 2: 82% of mild AD patients (MMSE>=20) showed mean 2.6-point ADAS-Cog12 improvement (p=0.0046); no drug-related adverse events.
Reduction in TNF alpha significantly correlated with cognitive improvement (R=0.70, p=0.0077).
Phase 3 AD trial (NCT04669028) 50% enrolled of 316 target; DSMB review later in 2022 may adjust sample size up to 400; topline expected mid-2023.
Phase 2 Parkinson's trial (NCT05083260) enrolling 40 patients; data readout by end of 2022; no drug-related AEs seen yet.
Phase 2b BIV201 trial in refractory ascites enrollment delayed by COVID; data readout now anticipated by mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.